The Most Respected CEO 2024
MultiplexDX CEO Honored as Slovakia’s Most Respected CEO 2024
We are proud to announce that our CEO, Pavol Čekan, has been awarded the title of Slovakia’s Most Respected CEO 2024. This prestigious recognition, organized by Forbes Slovakia in collaboration with PwC Slovakia, is based on votes from leading CEOs and highlights exceptional leadership, innovation, and integrity in business.
This award is both a tremendous honor and a strong motivation for our CEO and the entire team at MultiplexDX International to continue pushing boundaries in the development of innovative diagnostic tests. Our mission remains clear: to help as many patients as possible in Slovakia and worldwide with faster, more accurate, and more reliable cancer diagnostics.
We extend our congratulations to all the nominees and express our gratitude to the organizers and the business community for recognizing the importance of science-driven innovation.
At MultiplexDX, this recognition is not only about one person, but also about the dedication of our entire scientific and management team, as well as our partners and supporters, who make our mission possible every day.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
